NCT07837323Completed
Flaxseed Oil, Olive Oil, and Their Combination on Hepatic and Metabolic Outcomes in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
This 16-week randomized controlled trial evaluated the effects of flaxseed oil, extra virgin olive oil, and their combination on biochemical hepatic and metabolic outcomes in patients with MAFLD. The study assessed CK-18 as the primary outcome, with BMI, HbA1c, liver enzymes, and lipid profile as secondary outcom
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 112 (actual)
- First submitted
- 9 Sept 2026
- Start date
- 25 Jun 2024
- Primary completion date
- 26 Jun 2024
- Lead sponsor
- University of Lahore
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07837323
What you commit to
- Study type: Interventional
- Participants enrolled: 112
- From 25 Jun 2024 to the primary completion date, 26 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who had initiated or changed hypoglycemic, lipid-lowering, antihypertensive, hepatoprotective, corticosteroid, or weight-loss medications within the three months preceding enrollment were excluded,
Other illness
- Pregnant or lactating women, individuals with known allergies or hypersensitivity to flaxseed, olive oil, or other herbal products used in the intervention,
- participants with severe hepatic, renal, cardiovascular, or other systemic diseases that could interfere with the study outcomes
Who the study is looking for
- Participants aged 45-65 years, with a confirmed diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD),
- a body mass index (BMI) ≥25 kg/m²,
- HbA1c ≥5.7%,
- elevated serum cytokeratin-18 (CK-18)
Age in the registry: 45 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sana Noreen Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.